Clinical characteristics and next generation sequencing results analysis of acute myeloid leukemia patients dying early
10.3760/cma.j.cn115356-20231031-00065
- VernacularTitle:早期死亡的急性髓系白血病患者临床特征及二代测序结果分析
- Author:
Jixian HUANG
1
;
Yuquan LI
;
Xiaobo YAN
;
Guopan YU
;
Xiru HUANG
Author Information
1. 汕头大学医学院附属粤北人民医院血液内科，韶关 512025
- Keywords:
Leukemia, myeloid, acute;
Death;
Next generation sequencing
- From:
Journal of Leukemia & Lymphoma
2024;33(6):334-338
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical characteristics and next generation sequencing (NGS) results of acute myeloid leukemia (AML) patients dying early.Methods:A retrospective case series study was performed. The clinical data of 49 AML patients dying early in the Affiliated Yuebei People's Hospital of Shantou University Medical College from January 2016 to May 2021 were retrospectively analyzed. All patients were divided into 10 cases in the very early death group (death occurred within 3 d after diagnosis) and 38 cases in the non-very early death group (death occurred within 4-30 d after diagnosis). NGS was used to detect 196 mutant genes related to hematological malignancies.Results:The white blood cell count, creatinine level, lactate dehydrogenase level, bone marrow original cells proportion in the very early death group were higher than those in the non-very early death group, and the differences were statistically significant (all P < 0.05). Among 48 AML patients dying early, 34 cases had NGS results, among which the very early death occurred in 5 cases and the non-very early death occurred in 29 cases. Gene mutations were detected in 34 patients; finally 32 mutant genes were detected and 33 cases (97.06%) harbored more than 2 gene mutations, and the median number [ M ( Q1, Q3)] of gene mutations was 3 (2, 4). Conclusions:AML patients dying early harbor more than 2 gene mutations involving multiple signaling pathways. The clinical characteristics of AML patients in the very early death group are different from those of patients in the non-very early death group.
